Institutional investors hold a majority ownership of IMGN through the 85.49% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended September 2013, these large investors purchased a net $510.4 thousand shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CLEARBRIDGE INVESTMENTS LLC Bought 1.6 Million shares of Immunogen Inc
FIRST TRUST ADVISORS LP Bought 494.0 Thousand shares of Immunogen Inc
BLACKROCK FUND ADVISORS Bought 326.8 Thousand shares of Immunogen Inc